Skip to main content

Table 3 The association between inositol intake and lipid profiles based on subgroup analysis

From: The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials

Variables Number of SMD included Subgroups Pooled OR (random effect) 95% CI I2 (%) Overall I2 (%)
Triglycerides Type of disease 5 PCOS −0.74 −1.66, 0.18 91.7 93.2
7 Non-PCOS −1.58 −2.32, −0.85 92.1
Dosage of inositol (mg/day) 6 ≥2000 −0.83 −1.49, − 0.18 83.4
6 <2000 −1.69 −2.69, −0.68 96.2
Duration of study (week) 5 ≥14 −1.64 −2.94, −0.34 93.4
7 <14 −0.99 −1.67, − 0.32 93.1
Type of intervention 4 DCI −0.32 −0.66, 0.01 0.0
6 MI −1.15 −1.91, −0.39 94.0
2 MI + DCI −3.37 −6.00, −0.75 94.2
Total cholesterol Type of disease 5 PCOS −0.86 −1.72, − 0.02 90.3 93.6
6 Non-PCOS −1.49 −2.51, −0.46 95.5
Dosage of inositol (mg/day) 5 ≥2000 −0.82 −1.91, 0.28 92.2
6 <2000 −1.51 −2.38, −0.63 95.2
Duration of study (week) 5 ≥14 −1.77 −3.31, −0.22 95.0
6 <14 −0.74 −1.33, − 0.15 90.5
Type of intervention 4 DCI −0.22 −0.62, 0.18 26.2
5 MI −0.91 −1.59, − 0.24 91.9
2 MI + DCI −3.76 −5.68, −1.85 88.2
LDL-cholesterol Type of disease 3 PCOS −0.60 −1.51, 0.31 86.1 92.2
2 Non-PCOS −1.84 −3.41, 0.26 93.1
Dosage of inositol (mg/day) 3 ≥2000 −0.86 −2.27, 0.54 93.2
2 <2000 −2.00 −3.98, −0.03 94.8
Duration of study (week) 4 ≥14 −1.39 −2.78, −0.01 94.0
1 <14 −1.03 − 1.37, −0.70 0.0
Type of intervention 2 DCI −0.15 − 0.61, 0.30 0.0
1 MI −1.03 −1.37, −0.70
2 MI + DCI −2.59 −3.39, −1.81 56.7
HDL-cholesterol Type of disease 3 PCOS 0.38 0.12, 0.64 2.4 89.4
7 Non-PCOS 0.14 −0.56, 0.84 92.7
Dosage of inositol (mg/day) 5 ≥2000 0.01 −0.59, 0.62 81.1
5 <2000 0.37 −0.31, 1.04 92.2
Duration of study (week) 4 ≥14 −0.61 −1.35, 0.14 83.5
6 <14 0.68 0.42, 0.95 55.1
Type of intervention 3 DCI 0.19 −0.17, 0.55 0.0
5 MI 0.72 0.42, 1.02 62.0
2 MI + DCI −1.22 −1.73, −0.71 36.2
  1. MI myo-inositol, DCI D-chiro-Inositol, PCOS polycystic ovary syndrome